

IL2RA

Humanized Anti-IL-2R alpha (Daclizumab) mAb

| | | | |
|---------------------------------|---|------------------|----------------|
| Catalog No. | CSB102A CSB102B | Quantity: | 100 µg 1 mg |
| Alternate Names: | BIIB019, DAC HYP, Zinbryta | | |
| Description: | Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25), Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. In 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in <i>de novo</i> allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients. This decision was not related to any safety concerns associated with the use of Zenapax (daclizumab). Biogen's and Abbvie's Zinbryta (daclizumab), indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016. | | |
| UniProt ID (target): | P01589 | | |
| Source: | CHO cell line | | |
| Isotype: | Humanized IgG1 kappa | | |
| Concentration: | 1.0 mg/ml | | |
| Specificity: | Human IL-2RA | | |
| Biological Activity: | Blocks IL-2 receptors EC ₅₀ = 175.8 ng/ml, Daclizumab binding IL2RA by ELISA | | |
| Purity: | > 95% as determined by SDS-PAGE | | |
| Formulation: | PBS, pH 7.5 | | |
| Applications: | Functional studies, ELISA | | |
| Storage & Stability: | Store at 2-8°C for up to 1 week, or undiluted in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.